Continuation of dabigatran therapy in "real-world" practice in Hong Kong

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Ho, Mei Han ^a   Ho, Chi Wai ^a   Cheung, Emmanuel ^a   Chan, Pak Hei ^a   Hai, Jo Jo ^a   Chan, Koon Ho ^b   Chan, Esther W ^a   Leung, Gilberto Ka Kit ^b   Tse, Hung Fat ^a   Siu, Chung Wah ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; HISTAMINE H2 RECEPTOR ANTAGONIST; PROTON PUMP INHIBITOR; ANTITHROMBIN; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CHINESE; COST; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HONG KONG; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; AGED; ANALOGS AND DERIVATIVES; COMPLICATION; HEMORRHAGE; MIDDLE AGED; MORTALITY; RISK FACTOR; STROKE; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HONG KONG; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84905457264     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0101245     Document Type: Article

References (23)

1. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, et al. (2010) Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 12: 1360-1420.
2. Lip GY, Tse HF, Lane DA (2012) Atrial fibrillation. Lancet 379: 648-661.
3. Li SY, Zhao XQ, Wang CX, Liu LP, Liu GF, et al. (2012) One-year clinical prediction in Chinese ischemic stroke patients using the CHADS2 and CHA2DS2-VASc scores: the China National Stroke Registry. CNS Neurosci Ther 18: 988-993.
4. Zhang LF, Yang J, Hong Z, Yuan GG, Zhou BF, et al. (2003) Proportion of different subtypes of stroke in China. Stroke 34: 2091-2096. (Pubitemid 37099817)
5. Huang CY, Chan FL, Yu YL, Woo E, Chin D (1990) Cerebrovascular disease in Hong Kong Chinese. Stroke 21: 230-235. (Pubitemid 20067924)
6. Yang QD, Niu Q, Zhou YH, Liu YH, Xu HW, et al. (2004) Incidence of cerebral hemorrhage in the Changsha community. A prospective study from 1986 to 2000. Cerebrovasc Dis 17: 303-313. (Pubitemid 38621544)
7. Tse HF, Wang YJ, Ai-Abdullah MA, Pizarro-Borromeo AB, Chiang CE, et al. (2013) Stroke Prevention in Atrial Fibrillation - An Asian Stroke Perspective. Heart Rhythm 10(7): 1082-1088.
8. Chien KL, Su TC, Hsu HC, Chang WT, Chen PC, et al. (2010) Atrial fibrillation prevalence, incidence and risk of stroke and all-cause death among Chinese. Int J Cardiol 139: 173-180.
9. Lin LY, Lee CH, Yu CC, Tsai CT, Lai LP, et al. (2011) Risk factors and incidence of ischemic stroke in Taiwanese with nonvalvular atrial fibrillation - a nation wide database analysis. Atherosclerosis 217: 292-295.
10. Chan HT, So LT, Li SW, Siu CW, Lau CP, et al. (2011) Effect of herbal consumption on time in therapeutic range of warfarin therapy in patients with atrial fibrillation. J Cardiovasc Pharmacol 58: 87-90.
11. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, et al. (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361: 1139-1151.
12. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YP, et al. (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. ANNALS OF INTERNAL MEDICINE 145: 247-254. (Pubitemid 46768608)
13. Redfield MM, Jacobsen SJ, Burnett JC Jr, Mahoney DW, Bailey KR, et al. (2003) Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA 289: 194-202. (Pubitemid 36068707)
14. Siu CW, Yeung CY, Lau CP, Kung AW, Tse HF (2007) Incidence, clinical characteristics and outcome of congestive heart failure as the initial presentation in patients with primary hyperthyroidism. Heart 93: 483-487. (Pubitemid 46631516)
15. Ho LY, Siu CW, Yue WS, Lau CP, Lip GY, et al. (2011) Safety and efficacy of oral anticoagulation therapy in Chinese patients with concomitant atrial fibrillation and hypertension. J Hum Hypertens 25: 304-310.
16. Miyamoto K, Aiba T, Nakajima I, Yamada Y, Okamura H, et al. (2014) Efficacy and safety of novel anticoagulant dabigatran in clinical practice for Japanese patients with non-valvular atrial fibrillation. Journal of Arrhythmia 30(1): 58-64.
17. Ho JC, Chang AM, Yan BP, Yu CM, Lam YY, et al. (2012) Dabigatran compared with warfarin for stroke prevention with atrial fibrillation: experience in Hong Kong. Clin Cardiol 35: E40-45.
18. Tsivgoulis G, Krogias C, Sands KA, Sharma VK, Katsanos AH, et al. (2014) Dabigatran etexilate for secondary stroke prevention: the first year experience from a multicenter short-term registry. Ther Adv Neurol Disord 7: 155-161.
19. Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, et al. (2013) The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. Circulation 128: 237-243.
20. Nieuwlaat W, Healy J, Ezekowitz M, Reilly P, Formell S, et al. (2014) Management of dyspepsia symptoms on dabigatran during RELY-ABLE: Long-term follow-up study after RE-LY. European Heart J 34(suppl 1). doi: 10.1093/eurheartj/eht307.P549.
21. Hori M, Ezekowitz MD, Reilly PA (2014) Response to letter regarding article, "dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in asians and non-asians with atrial fibrillation". Stroke 45: e43.
22. Yap LB, Rusani BI, Umadevan D, Muhammad Z, Hussin A, et al. (2014) A single centre experience of the efficacy and safety of dabigatran etexilate used for stroke prevention in atrial fibrillation. J Thromb Thrombolysis 38(1): 39-44.
23. Michel J, Mundell D, Boga T, Sasse A (2013) Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data. Heart Lung Circ 22: 50-55.